Venetoclax

1:12
Frontline, fixed-duration venetoclax/obinutuzumab: PFS and MRD data from CLL14
Barbara Eichhorst
3:02
Tailored treatment strategies for CLL
Danielle Brander
3:58
Mantle cell lymphoma update: changing times & latest news
Simon Rule
2:30
ViPOR regimen for R/R B-cell lymphoma
Wyndham Wilson
2:00
Venetoclax plus rituximab or obinutuzumab in CLL after alloHCT
Othman Al-Sawaf
2:39
Does chemotherapy still have a role in the treatment of Waldenström’s?
Steven Treon
3:35
Venetoclax: undetectable peripheral blood MRD status as a therapeutic goal in R/R CLL
Sasanka Handunnetti
3:07
CLL14 trial analysis
Othman Al-Sawaf
2:29
Combo of RG6146/venetoclax/rituximab for R/R DLBCL: initial data
Michael Dickinson
2:27
Venetoclax plus dose-adjusted R-EPOCH for Richter’s: results of the CRC043 trial
Matthew Davids
1:20
CLL treatment for the old and young
Matthew Davids
1:24
Time-limited therapy in CLL
Barbara Eichhorst
0:52
Here’s looking at you: CLL research to watch
Barbara Eichhorst
1:14
CLL14 trial thoughts
Constantine Tam
3:55
CLL trial highlights from 15-ICML
Ahmad Alhuraiji
2:04
Emerging therapies in AML: why patients should be optimistic
Naval Daver
VJHemOnc VJHemOnc is intended for Healthcare Professionals only

By choosing to continue, you are confirming that you are a healthcare professional

VJHO needs the contact information you provide to inform you about our latest hemonc news and videos, educational courses and industry supported content (some of which may be promotional in nature). You may unsubscribe from these communications at anytime. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy.

The content of VJHemOnc is intended for healthcare professionals